retatrutide schedule VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Starting Dose | Everest

The GLP-1 receptor activation is supraphysiological, meaning it far exceeds what the body would ever produce naturally

Currently, the core registration studies to assess the efficacy of retatrutide include: TRIUMPH-1 : A randomized, double-blind, placebo-controlled trial to test the safety and effectiveness of a treatment for people with obesity or overweight, including those with OSA and OA, but without type 2 diabetes

doi: 10.1161/CIRCULATIONAHA.118.038868 67 CarusoICignarelliASoriceGPNatalicchioAPerriniSLaviolaLet al

doi:10.1002/dmrr.70058 Tang B, Sjlander A, Wastesson JW, et al

References Holst, J

These predispositions should be interpreted with your qualified healthcare provider in context of your complete clinical picture, baseline lipid profile, and overall cardiometabolic health